Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Extrahepatic Bile Duct Cancer
			Gastric Cancer
			Gastrointestinal Carcinoid Tumor
			Liver Cancer
			Pancreatic Cancer
			Small Intestine Cancer
2		Additional conditions recognized in this trial
			Bile Duct Neoplasms
			Carcinoid Tumor
			Duodenal Neoplasms
			Gastrointestinal Neoplasms
			Ileal Neoplasms
			Intestinal Neoplasms
			Jejunal Neoplasms
			Liver Neoplasms
			Malignant Carcinoid Syndrome
			Pancreatic Neoplasms
			Stomach Neoplasms
3		More general conditions related to this trial
			Adenocarcinoma
			Bile Duct Diseases
			Biliary Tract Diseases
			Biliary Tract Neoplasms
			Carcinoma
			Digestive System Diseases
			Digestive System Neoplasms
			Duodenal Diseases
			Endocrine Gland Neoplasms
			Endocrine System Diseases
			Gastrointestinal Diseases
			Ileal Diseases
			Intestinal Diseases
			Jejunal Diseases
			Liver Diseases
			Neoplasms
			Neoplasms by Histologic Type
			Neoplasms by Site
			Neoplasms, Germ Cell and Embryonal
			Neoplasms, Glandular and Epithelial
			Neoplasms, Nerve Tissue
			Neuroectodermal Tumors
			Neuroendocrine Tumors
			Pancreatic Diseases
			Stomach Diseases
4		Interventions listed in this trial
			filgrastim
			fluorouracil
			hydroxyurea
			recombinant interferon alfa
5		Additional drug interventions recognized in this trial
			Interferon Alfa-2a
			Interferon Alfa-2b
			Interferon Type I, Recombinant
			Interferon-alpha
			Interferons
6		More general drug interventions related to this trial
			Angiogenesis Inhibitors
			Angiogenesis Modulating Agents
			Anti-Infective Agents
			Antimetabolites
			Antimetabolites, Antineoplastic
			Antineoplastic Agents
			Antisickling Agents
			Antiviral Agents
			Enzyme Inhibitors
			Growth Inhibitors
			Growth Substances
			Hematologic Agents
			Immunologic Factors
			Immunosuppressive Agents
			Molecular Mechanisms of Pharmacological Action
			Nucleic Acid Synthesis Inhibitors
			Pharmacologic Actions
			Physiological Effects of Drugs
			Therapeutic Uses
7		Sponsors listed in this trial
			Albert Einstein College of Medicine of Yeshiva University
			National Cancer Institute (NCI)